Equity
Total Liabilities & Equity
Royalty Pharma Total Liabilities & Equity increased by 1.0% to $19.82B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 12.5%, from $17.61B to $19.82B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows an upward trend with a 4.1% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
StatementBalance Sheet Statement
SectionEquity
CategoryOther
SignalHigher is better
VolatilityStable
First reportedQ4 2015
Last reportedQ1 2026
How to read this metric
Growth in this figure generally indicates an expansion of the company's asset base and operational scale.
Detailed definition
This is the sum of all financial obligations and shareholder equity, which must mathematically equal total assets. It re...
Peer comparison
Standard balance sheet total; used as a denominator for various leverage and efficiency ratios across all industries.
Metric ID:
total_liabilities_and_equityHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $16.51B | $17.73B | $17.52B | $17.38B | $17.74B | $17.67B | $16.81B | $17.07B | $17.12B | $15.86B | $16.38B | $16.13B | $17.66B | $18.04B | $18.22B | $17.61B | $18.32B | $19.35B | $19.62B | $19.82B |
| QoQ Change | — | +7.4% | -1.2% | -0.8% | +2.1% | -0.4% | -4.9% | +1.6% | +0.3% | -7.4% | +3.3% | -1.5% | +9.5% | +2.2% | +1.0% | -3.4% | +4.1% | +5.6% | +1.4% | +1.0% |
| YoY Change | — | — | — | — | +7.4% | -0.3% | -4.0% | -1.8% | -3.5% | -10.3% | -2.6% | -5.5% | +3.1% | +13.8% | +11.2% | +9.2% | +3.8% | +7.2% | +7.7% | +12.5% |
Range$15.86B – $19.82B
CAGR+3.9%
Avg YoY Growth+3.0%
Median YoY Growth+3.4%
Current Streak4 quarters growth
Total Liabilities & Equity at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's total liabilities & equity?
- Royalty Pharma (RPRX) reported total liabilities & equity of $19.82B in Q1 2026.
- How has Royalty Pharma's total liabilities & equity changed year-over-year?
- Royalty Pharma's total liabilities & equity increased by 12.5% year-over-year, from $17.61B to $19.82B.
- What is the long-term trend for Royalty Pharma's total liabilities & equity?
- Over 5 years (2020 to 2025), Royalty Pharma's total liabilities & equity has grown at a 4.1% compound annual growth rate (CAGR), from $16.02B to $19.62B.
- What does total liabilities & equity mean?
- The total amount of funding the company has received from both creditors and shareholders.